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1. Introduction 
Substance P, a hypotensive and smooth muscle 
contracting agent, was first found in equine brain and 
intestinal extracts [ 11. The active compound was iso- 
lated in pure form from bovine hypothalami and was 
found to be an undecapeptide of the structure: Arg- 
Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met - 
NH2 [2,3]. The highest concentrations of SP have been 
found in the hypothalamus, the spinal cord and the ner- 
vous system supplying the gastro-intestinal tract. Pref- 
erential localization of SP in the dorsal column of the 
spinal cord and its ability to excite spinal motoneurons 
suggest hat SP is involved in sensory transmission 
[4,5]. The presence of SP in the peripheral plasma 
raised the possibility that the peptide can be released 
into the blood stream and act like a hormone on distal 
organs [6-81. However, intravenous application of 
SP results in short-lived effects that hamper detailed 
analysis of its function. Proteolytic degradation of 
SP was observed in various smooth muscle [9] and 
brain [lo-121 preparations and in plasma [7,9,13]. 
Although metabolically stable analogs of SP could be 
useful in studies of SP action, to data no such analog 
has been reported. In an effort to prepare metabolic- 
ally stable SP analogs we have chosen the hexapeptide 
[pGlu6]SP,_,, as the parent compound and synthe- 
sized peptide analogs in which specific amino acid 
residues were substituted by the corresponding 
N-methyl derivatives. Peptides containing N-methyl 
amino acid residues are resistant to the action of vari- 
ous proteolytic enzymes [14-l 71 and produce pro- 
tracted biological activities in vivo [18,19]. 
2. Materials and methods 
2.1. Synthesis 
Boc-N-methyl phenylalanine (Boc N-MePhe) and 
Boc-N-methyl leucine (Boc N-MeLeu) were prepared 
according to [20]. Peptides were synthesized in solu- 
tion by stepwise coupling of Boc amino acids from 
the C-terminal end. Coupling was effected by the 
excess mixed anhydride method, using isobutylchloro- 
formate [21]. Deprotection was achieved by 4 N HCl 
in acetic acid. All peptides as,well as intermediate 
compounds were characterized by elemental analysis, 
melting point, optical rotation and amino acid analysis. 
Purity was assessed by TLC and reverse-phase HPLC. 
2.2. In vitro assays of SP analogs 
Parotid slice system: Rat parotid slices were pre- 
pared and incubated as in [22]. To prevent adsorp- 
tion of the hydrophobic peptides to glass, vials were 
pretreated with 1% t rimethylchlorosilane in toluene, 
and gelatin (0.1%) was added to the incubation 
medium. Stock solutions and appropriate dilutions of 
SP analogs were prepared in N,/V-dimethylformamide 
(DMF). Aliquots of IO-20 PM of the agonist solution 
were added to the slice system. In control systems, 
1% DMF had no deleterious effect on K’ release or 
its reuptake into the slices. ED5,-, is the concentration 
of analog required to produce half-maximal K’ release 
within 2 min from its addition to the slice system. 
Relative potency is the ED5,, ratio of the analog and 
that of [~GIu~]SP~_~,, expressed as %. The figures 
show the results of typical experiments, each repeated 
for at least 4 times. A control system containing the 
parent compound [pGlu6]SP6_,, was included in 
each experiment. 
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Isolated guinea pig ileum assay was done as in 
v31. 
3. Results 
25 
20 I h 
Studies of SP degradation by chymotrypsin [3] 
and papain [24] as well as by a partially purified 
brain neutral protease [ 111 indicated that the peptide 
is cleaved at the Gln6-Phe7 or Phe’-Phea and at the 
Gly’-Leur’ bonds. We report here on structural 
analogs of SP which were designed to resist proteolytic 
cleavage of these specific peptide bonds. The hexa- 
peptide pGlu-Phe-Phe-Gly-Leu-Met--N& 
( [pGlu6]SP,_r,) was chosen as the parent compound, 
as this hexapeptide is as potent as the whole undeca- 
peptide both in the guinea pig ileum and in the rat 
parotid assays. Furthermore, the presence of blocked 
amino- and carboxy-terminals protects the hexapep- 
tide against amino and carboxy exopeptidases. To 
prevent hydrolysis of the Gln6-Phe’ and Gly’-Leu” 
bonds the analogs [pGlu6, N-MePhe7] SP& rr and 
[pGlu6, N-MeLerr”] SP,_,, were prepared. The ana- 
ogs and the unmodified parent compound were tested 
on rat parotid slices. Addition of [pGlu6]SP,_,r to 
the parotid slice system initiated a rapid and transient 
release of K’ from the cells. Maximal K’ release was 
achieved within 2 min, after which time the amount 
of K’ in the medium decreased ue to reuptake of 
K’ into the cells (fig.1). We have shown that the 
transient effect of SP on the parotid slice system is 
due to inactivation of the peptide and not due to a 
decline in the response of the tissue [22]. The inacti- 
vation of the peptide in this system is probably caused 
by proteolytic cleavage, as addition of bacitracin (1 
mg/ml) caused a delay in reuptake of K’ into the 
slices (not shown). The peak amount of K’ release 
into the medium was used to assay the potency of the 
analogs and the delay in reuptake of the released K’ 
was used to assess their metabolic stability. It should 
be pointed out that in order to test the metabolic 
stability of an analog, the peptide has to be applied 
at concentrations that do not saturate the receptor. 
At supersaturating concentrations, considerable 
degradation of the peptide can take place without 
effect on receptor occupancy. 
Addition of the analog [pGlu6,N-MeLeu”]SP,_,r 
to the parotid slice system caused a rapid K’ release 
like that elicited by the unmodified hexapeptide, but 
net reuptake of the released K’ was observed only 
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Fig.1. Time course of K’ release from rat parotid slices caused 
by the addition of [pGlu6]SP,_,, (Q) 40 nM, (0) 5 PM at 
zero time. 
after a considerable delay and proceeded at a slow 
rate. The effect of [pGlu6,N-MeLeu’o]SP,_,, on 
K’ release decreased to its half-maximal extent in 60 
min (fig.2). The relative potency of this analog was 
45 + 5%. Application of the analog [pGlu6,N-MePhe7]- 
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F’ip.2. Time course ofK+ release from rat parotid slices caused 
by the addition of [pC;lu6,N-MeLeu” ]SP,_,, 80 nM at 
zero time. 
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Fig.3. Time course of K' release from rat parotid slices caused 
by the addition of [ pGluh ,N-MePhe’ 1 Sp, _, , 1.5 PM at zero 
time. 
SP,_,, to the parotid slice system gave a transient 
K’ release similar in its kinetics to that of [pGlu6]- 
SP,_,, (fig.3). The potency of [pGlu6, N-MePhe7]- 
SP6__lI was decreased to 5 f 1% of that of the unmodi- 
fied parent compound. 
Despite the fact that a single substitution of Phe7 
by N-MePhe did not confer metabolic stability and 
yielded an analog of low potency we have substituted 
both Leu” and Phe7 by their correspondingN-methyl 
derivatives. The analog [pGlu6,N-MePhe7, N-MeLeu”]- 
SP,_,, was found to have a relative potency of 4 + 
1% but its effect on K’ release did not significantly 
decrease within 60 min of incubation (fig.4). Appar- 
ently the introduction into the hexapeptide of 
N-MePhe together with N-MeLeu further increases 
the metabolic stability contributed by a single substi- 
tution with N-MeLeu. When tested at saturating con- 
centrations, the 3 N-methylated analogs were full 
agonists of SP and have similar activity both in the 
parotid and in the isolated guinea pig ileum assay. 
4. Discussion 
The transient K’ release evoked by SP action on 
rat parotid slices has been shown to be due to inacti- 
:pGl@, N-Me-Phe7, N-Me-Led’] sP6+ 
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Fig.4. Time course of K'release from rat parotid slices caused 
by the addition of [pGlu6, N-MePhe’,N-MeLeu”]SP,._,, 
(0) 1 PM), (0) 3 PM at zero time. 
vation of the peptide rather than due to a decline in 
the response of the tissue [22]. The apparent lack of 
desensitization of the SP response in the parotid 
slices makes it a suitable preparation to test the meta- 
bolic stability of SP analogs. This is in contrast to 
cells of other tissues in which desensitization of the 
response to SP rapidly occurs [25]. Another advantage 
of the test system is the rather homogenous popula- 
tion of acinar cells which comprise -90% of the cell 
mass of the parotid. It is thus likely that the same 
cells which respond to SP are also involved in the 
inactivation of the peptide. 
The approach used in the present study was to 
stabilize particular peptide bonds in the C-terminal 
hexapeptide sequence of SP that were found suscepti- 
ble to cleavage by proteolytic enzymes. The Gly9- 
Leu” and pGlu6-Phe7 peptide bonds were stabilized 
by substituting Leu’” or Phe7 by their N-methyl- deri- 
vatives. The effects of the analogs on the parotid sys- 
tem indicate that stabilization of the Gly’-Leu” 
bond yields a potent analog which demonstrates a 
considerably more persistent action on the parotid 
slices than the parent compound. On the other hand, 
293 
Volume 123, number 2 FEBS LETTERS January 198 1 
stabilization of the pClu6--Phe’ bond by incorpora- 
tion of IV-MePhe’ greatly reduces the potency of the 
analog and by itself does not produce a persistently 
acting analog. However, substitution of both Leu” 
and Phe’ by their N-methyl derivatives resulted in an 
analog which was much more stable than the analog 
containing only N-MeLeu”. These results could be 
explained by assuming that the Glyg-Leu” bond is 
cleaved by the parotid slice system at a much faster 
rate than the pGl&Phe’ bond. The small amounts 
of analogs which are used in the parotid assay makes 
it difficult to demonstrate a direct correlation between 
persistent action of the analogs and their resistance to 
proteolytic cleavage without the use of radioactively 
labeled compounds. We have, however, tested the 
stability of the analogs to proteolytic cleavage by 
several endopeptidases. These studies showed that the 
analog [pGlu6, N-MePhe’, N-MeLeu”] SP6_ II was 
resistant to degradation by pepsin, chymotrypsin, 
papain and thermolysin, using concentrations of these 
enzymes which resulted in rapid breakdown of the 
unmodified parent compound. It is hoped that this 
analog which combines full agonistic activity with 
resistance to proteolytic cleavage will prove useful 
in further studies of SP action. 
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